BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
17 September 2024 - 8:45PM
UK Regulatory
BioNTech to Host AI Day as an Edition of its Innovation Series on
October 1, 2024
MAINZ, Germany, September 17, 2024
(GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX,
“BioNTech”), alongside its artificial intelligence (“AI”) company
InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of
BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST)
on Tuesday, October 1st, 2024 in London, United Kingdom.
The event will provide an overview of BioNTech’s and InstaDeep’s AI
strategy and capabilities, and the application of AI in BioNTech’s
pipeline and internal processes.
The live webcast of the event will be available
via this link.
A replay of the webcast will be available
shortly after the event’s conclusion and archived on BioNTech’s
website for one year after.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next
generation immunotherapy company pioneering novel therapies for
cancer and other serious diseases. BioNTech exploits a wide array
of computational discovery and therapeutic drug platforms for the
rapid development of novel biopharmaceuticals. Its broad portfolio
of oncology product candidates includes individualized and
off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor (CAR) T cells, several protein-based therapeutics,
including bispecific immune checkpoint modulators, targeted cancer
antibodies and antibody-drug conjugate (ADC) therapeutics, as well
as small molecules. Based on its deep expertise in mRNA vaccine
development and in-house manufacturing capabilities, BioNTech and
its collaborators are developing multiple mRNA vaccine candidates
for a range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global and specialized pharmaceutical collaborators,
including Biotheus, DualityBio, Fosun Pharma, Genentech, a member
of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and
Regeneron.
For more information, please visit
www.BioNTech.com.
CONTACTS
Media Relations
Jasmina Alatovic
+49 (0) 6131 9084 1513
Media@biontech.de
Investor Relations
Victoria Meissner, M.D.
Investors@biontech.de
BioNTech (TG:22UA)
Historical Stock Chart
From Oct 2024 to Nov 2024
BioNTech (TG:22UA)
Historical Stock Chart
From Nov 2023 to Nov 2024
